Home›Stock Screener›Accretion Pharmaceuticals›Financial Statements

Accretion Pharmaceuticals Complete Financial Statements

3 Years of Data
2026 - 2024

In FYNone, Accretion Pharmaceuticals (ACCPL) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 11.1% and ROE of 18.2%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Compare with ACCPL fundamental valuation to assess whether the stock is under or overvalued.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 11.11% 2026 data
EBITDA Margin 16.67% 2026 data
Operating Margin 17.00% 2026 data
Return on Assets 12.99% 2026 data
Return on Equity 18.18% 2026 data

Balance Sheet Ratios

Current Ratio 61.00 2026 data
Equity Ratio 71.43% 2026 data
Asset Turnover 1.17 2026 data

ACCPL Revenue, Net Profit & EBITDA — Year-on-Year Growth

ACCPL YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+92.5%
Year-over-Year
Equity Growth
+266.7%
Year-over-Year
Operating Cash Flow Growth
+150.0%
Year-over-Year
Investing Cash Flow Growth
+66.7%
Year-over-Year
Financing Cash Flow Growth
-123.5%
Year-over-Year

ACCPL Income Statement — Revenue, EBITDA & Net Profit

Accretion Pharmaceuticals revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 11.1%. For live price, earnings ratios and company overview, see Accretion Pharmaceuticals share price screener.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024
Revenue 0 90 58 13
Expenses 0 75 46 11
EBITDA 0 15 12 3
Operating Profit Margin % 0.00% 17.00% 21.00% 19.00%
Depreciation 0 1 1 0
Interest 0 1 1 0
Profit Before Tax 0 13 10 2
Tax 0 3 3 1
Net Profit 0 10 7 2
Earnings Per Share (₹) 0.00 9.03 8.48 1.96

ACCPL Balance Sheet — Assets, Liabilities & Shareholders' Equity

ACCPL total assets ₹77 Cr, total equity ₹55 Cr, total liabilities ₹ Cr (2026) — ROE 18.2%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024
ASSETS
Total Assets 77 40 27
Current Assets 61 34 22
Fixed Assets 13 6 5
Capital Work in Progress 0 0 0
Investments 28 0 0
Other Assets 0 34 22
LIABILITIES
Total Liabilities
Current Liabilities 1 1 7
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 55 15 6
Share Capital 11 8 4
Reserves & Surplus 44 7 2

ACCPL Cash Flow Statement — Operating, Investing & Financing

Accretion Pharmaceuticals operating cash flow ₹6 Cr, investing ₹-2 Cr, financing ₹-4 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024
Operating Activities 6 -12
Investing Activities -2 -6
Financing Activities -4 17
Net Cash Flow 0 0